Lipids, lipoproteins, and cardiovascular disease: Clinical pharmacology now and in the future

Journal of Clinical Endocrinology and Metabolism

Volumn 101, Issue 3, 2016, Pages 804-814

  Chait, Alan ^a   Eckel, Robert H ^b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALIROCUMAB; ANTISENSE OLIGONUCLEOTIDE; APABETALONE; APOLIPOPROTEIN A; ATORVASTATIN; BEMPEDOIC ACID; BOCOCIZUMAB; EZETIMIBE PLUS SIMVASTATIN; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ICOSAPENTAENOIC ACID; LAROPIPRANT; LIPID; LIPOPROTEIN; LIPOPROTEIN LIPASE; LOMITAPIDE; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MIPOMERSEN; OMEGA 3 FATTY ACID; PLACEBO; PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9; ROSUVASTATIN; SERINE PROTEINASE; SIMVASTATIN; TORCETRAPIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERY LOW DENSITY LIPOPROTEIN; ADENOSINE TRIPHOSPHATE CITRATE SYNTHASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PCSK9 PROTEIN, HUMAN; TRIACYLGLYCEROL;

ACUTE CORONARY SYNDROME; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; DRUG SAFETY; DRUG TOLERABILITY; ENZYME ACTIVITY; ENZYME INHIBITION; ETHNIC DIFFERENCE; FAMILIAL HYPERCHOLESTEROLEMIA; GENE SILENCING; GENE THERAPY; HEART INFARCTION; HIGH RISK POPULATION; HUMAN; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; LIFESTYLE MODIFICATION; LIPID METABOLISM; LIPOPROTEIN METABOLISM; NONHUMAN; PRIORITY JOURNAL; PROTEIN TARGETING; ANTAGONISTS AND INHIBITORS; BLOOD; CARDIOVASCULAR DISEASES; CLINICAL TRIAL (TOPIC); METABOLISM; PHYSIOLOGY;

ATP CITRATE (PRO-S)-LYASE; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; CLINICAL TRIALS AS TOPIC; GENETIC THERAPY; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPIDS; LIPOPROTEINS; PROPROTEIN CONVERTASES; SERINE ENDOPEPTIDASES; TRIGLYCERIDES;

EID: 84960926720     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2015-3940     Document Type: Article

References (124)

1. Keys A. Cholesterol, "giant molecules, " and atherosclerosis. J Am Med Assoc. 1951;147:1514-1519.
2. Gofman JW, Lindgren F. The role of lipids and lipoproteins in atherosclerosis. Science. 1950;111:166-171.
3. Bilheimer DW, Grundy SM, Brown MS, Goldstein JL. Mevinolin stimulates receptor-mediated clearance of low density lipoprotein from plasmainfamilial hypercholesterolemia heterozygotes. Trans Assoc Am Physicians. 1983;96:1-9.
4. Marais AD, Naoumova RP, Firth JC, Penny C, Neuwirth CK, Thompson GR. Decreased production of low density lipoprotein by atorvastatin after apheresis in homozygous familial hypercho-lesterolemia. J Lipid Res. 1997;38:2071-2078.
5. Cholesterol Treatment Trialists (CTT) Collaborators, Mihaylova B, Emberson J, Blackwell L, et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012;380:581-590.
6. Cholesterol Treatment Trialists (CTT) Collaborators, Fulcher J, O'Connell R, Voysey M, et al. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174, 000 participants in 27 randomised trials. Lancet. 2015; 385:1397-1405.
7. Amarenco P. Effect of statins in stroke prevention. Curr Opin Lipidol. 2005;16:614-618.
8. Morrone D, Weintraub WS, Toth PP, et al. Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: a pooled analysis of over 21, 000 subjects from 27 clinical trials. Atherosclerosis. 2012; 223:251-261.
9. Margolis KL, Dunn K, Simpson LM, et al. Coronary heart disease in moderately hypercholesterolemic, hypertensive black and non-black patients randomized to pravastatin versus usual care: the antihyper-tensive and lipid lowering to prevent heart attack trial (ALLHAT-LLT). Am Heart J. 2009;158:948-955.
10. Pyörälä K, Pedersen TR, Kjekshus J, Faergeman O, Olsson AG, Thorgeirsson G. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S) [published erratum appears in Diabetes Care 1997 Jun;20(6): 1048]. Diabetes Care. 1997;20:614-620.
11. Haffner S, Alexander C, Cook T, et al. Reduced coronary events in simvastatin-treated subjects with coronary heart disease and diabetes or impaired fasting glucose: findings from the Scandinavian Simvastatin Survival Study (4S). Arch Int Med. 1999;159:2661-2667.
12. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-1389.
13. Khera AV, Everett BM, Caulfield MP, et al. Lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER Trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin). Circulation. 2014;129:635-642.
14. Cooper R, Cutler J, Desvigne-Nickens P, et al. Trends and disparities in coronary heart disease, stroke, and other cardiovascular diseases in the United States: findings of the national conference on cardiovascular disease prevention. Circulation. 2000;102:3137-3147.
15. O'Flaherty M, Buchan I, Capewell S. Contributions of treatment and lifestyle to declining CVD mortality: why have CVD mortality rates declined so much since the 1960s? Heart. 2013;99:159-162.
16. Wiviott SD, Cannon CP, Morrow DA, et al. Can low-density lipoprotein be too low? The safety and efficacy of achieving very low low-density lipoprotein with intensive statin therapy: a PROVE IT-TIMI22 substudy. J Am Coll Cardiol. 2005;46:1411-1416.
17. O'Keefe JH, Jr., Cordain L, Harris WH, Moe RM, Vogel R. Optimal low-density lipoprotein is 50 to 70 mg/dl: lower is better and physiologically normal. J Am Coll Cardiol. 2004;43:2142-2146.
18. Garcia-Calvo M, Lisnock J, Bull HG, et al. The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1). Proc Natl Acad Sci USA. 2005;102:8132-8137.
19. Cannon CP, Blazing MA, Giugliano RP et al; IMPROVE-IT Investigators. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372:2387-2397.
20. Jarcho JA, Keaney JF, Jr. Proof that lower is better-LDL cholesterol and IMPROVE-IT. N Engl J Med. 2015;372:2448-2450.
21. Seidah NG, Benjannet S, Wickham L, et al. The secretory propro-tein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation. Proc Natl Acad Sci USA. 2003;100:928-933.
22. Abifadel M, Varret M, Rabes JP, et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet. 2003;34: 154-156.
23. Poirier S, Mayer G, Benjannet S, et al. The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and Apo ER2. J Biol Chem. 2008;283:2363-2372.
24. Poirier S, Mayer G. The biology of PCSK9 from the endoplasmic reticulum to lysosomes: new and emerging therapeutics to control low-density lipoprotein cholesterol. Drug Des Devel Ther. 2013; 7:1135-1148.
25. Colhoun HM, Robinson JG, Farnier M, et al. Efficacy and safety of alirocumab, a fully human PCSK9 monoclonal antibody, in high cardiovascular risk patients with poorly controlled hypercholesterolemia on maximally tolerated doses of statins: rationale and design of the ODYSSEY COMBO I and II trials. BMC Cardiovasc Disord. 2014;14:121.
26. Koren MJ, Scott R, Kim JB, et al. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study. Lancet. 2012;380:1995-2006.
27. Navarese EP, Kolodziejczak M, Schulze V, et al. Effects of proprotein convertase subtilisin/kexin type 9 antibodies in adults with hypercholesterolemia: a systematic review and meta-analysis. Ann Intern Med. 2015;163:40-51.
28. Martin MJ, Hulley SB, Browner WS, Kuller LH, Wentworth D. Serum cholesterol, blood pressure, and mortality: implications from a cohort of 361, 662 men. Lancet. 1986;2:933-936.
29. Hsia J, Mac Fadyen JG, Monyak J, Ridker PM. Cardiovascular event reduction and adverse events among subjects attaining low-density lipoprotein cholesterol <50 mg/dl with rosuvastatin. The JUPITER trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin). J Am Coll Cardiol. 2011; 57: 1666-1675.
30. Robinson JG, Farnier M, Krempf M, etal;Investigators ODYSSEY LONGTERM. Efficacy and safetyof alirocumabin reducing lipids and cardiovascular events. N Engl J Med. 2015;372:1489-1499.
31. Sabatine MS, Giugliano RP, Wiviott SD, et al; Open-Label Study of Long-Term Evaluation against LDL Cholesterol (OSLER) Investigators. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372:1500-1509.
32. Lee J, Hegele RA. Abetalipoproteinemia and homozygous hypo-betalipoproteinemia: a framework for diagnosis and management. J Inherit Metab Dis. 2014;37:333-339.
33. Kostis WJ. How low an LDL-C should we go with statin therapy? Curr Atheroscler Rep. 2014;16:388.
34. Welty FK. Hypobetalipoproteinemia and abetalipoproteinemia. Curr Opin Lipidol. 2014;25:161-168.
35. Berriot-Varoqueaux N, Aggerbeck LP, Samson-Bouma M, Wetterau JR. The role of the microsomal triglygeride transfer protein in abetalipoproteinemia. Annu Rev Nutr. 2000;20:663-697.
36. Kayden HJ. Abetalipoproteinemia. Annu Rev Med. 1972;23:285-296.
37. Ballantyne CM, Davidson MH, Macdougall DE, et al. Efficacy and safety of a novel dual modulator of adenosine triphosphate-citrate lyase and adenosine monophosphate-activated protein kinase in patients with hypercholesterolemia: results of a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial. J Am Coll Cardiol. 2013;62:1154-1162.
38. Lemus HN, Mendivil CO. Adenosine triphosphate citrate lyase: emerging target in the treatment of dyslipidemia. J Clin Lipidol. 2015; 9:384-389.
39. Gutierrez MJ, Rosenberg NL, Macdougall DE, et al. Efficacy and safety of ETC-1002, a novel investigational low-density lipoprotein-cholesterol-lowering therapy for the treatment of patients with hy-percholesterolemia and type 2 diabetes mellitus. Arterioscler Thromb Vasc Biol. 2014;34:676-683.
40. Thompson PD, Rubino J, Janik MJ, et al. Useof ETC-1002 to treat hypercholesterolemia in patients with statin intolerance. J Clin Lipidol. 2015;9:295-304.
41. Pinkosky SL, Filippov S, Srivastava RA, et al. AMP-activated protein kinase and ATP-citrate lyase are two distinct molecular targets for ETC-1002, a novel small molecule regulator of lipid and carbohydrate metabolism. J Lipid Res. 2013;54:134-151.
42. Kastelein JJ, Wedel MK, Baker BF, et al. Potent reduction of apo-lipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B. Circulation. 2006;114:1729-1735.
43. Cuchel M, Bloedon LT, Szapary PO, et al. Inhibition of micro-somal triglyceride transfer protein in familial hypercholesterol-emia. N Engl J Med. 2007;356:148-156.
44. Cuchel M, Rader DJ. Microsomal transfer protein inhibition in humans. Curr Opin Lipidol. 2013;24:246-250.
45. Gordon DJ, Rifkind BM. High-density lipoprotein-the clinical implications of recent studies. N Engl J Med. 1989;321:1311-1316.
46. Miller GJ, Miller NE. Plasma high density lipoprotein concentration and development of ischaemic heart disease. Lancet. 1974;1: 16-20.
47. Voight BF, Peloso GM, Orho-Melander M, et al. Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet. 2012;380:572-580.
48. Barter PJ, Caulfield M, Eriksson M, et al; ILLUMINATE Investigators. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007;357:2109-2122.
49. Forrest MJ, Bloomfield D, Briscoe RJ, et al. Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone. Br J Pharmacol. 2008;154:1465-1473.
50. Schwartz GG, Olsson AG, Abt M, et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med 2012;367:2089-2099.
51. Investigators A-H. The role of niacin in raising high-density lipo-protein cholesterolto reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol rationale and study design. The Atherothrombosis Intervention in Metabolic syndrome with low HDL/high triglycerides: Impact on Global Health outcomes (AIM-HIGH). Am Heart J. 2011;161:471-477.
52. HPS2-THRIVE Collaborative Group, Landray MJ, Haynes R, Hopewell JC, et al. Effects of extended-release niacin with la-ropiprant in high-risk patients. N Engl J Med. 2014;371:203-212.
53. Canner PL, Berge KG, Wenger NK, et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol. 1986;8:1245-1255.
54. Coronary Drug Project report on clofibrate and niacin. Atherosclerosis. 1978;30:239-240.
55. Rubin EM, Ishida BY, Clift SM, Krauss RM. Expression of human apolipoprotein A-I in transgenic mice results in reduced plasma levels of murine apolipoprotein A-I and the appearance of two new high density lipoprotein size subclasses. Proc Natl Acad Sci USA. 1991;88:434-438.
56. Tangirala RK, Tsukamoto K, Chun SH, Usher D, Pure E, Rader DJ. Regression of atherosclerosis induced by liver-directed gene transfer of apolipoprotein A-I in mice. Circulation. 1999;100:1816-1822.
57. Hughes SD, Verstuyft J, Rubin EM. HDL deficiency in genetically engineered mice requires elevated LDL to accelerate atherogenesis. Arterioscler Thromb Vasc Biol. 1997;17:1725-1729.
58. Roheim PS. Atherosclerosis and lipoprotein metabolism: role of reverse cholesterol transport. Am J Cardiol 1986;57:3C-10C.
59. Badimon JJ, Fuster V, Badimon L. Roleofhigh density lipoproteins in the regression of atherosclerosis. Circulation. 1992;86:III86-III94.
60. Rosenson RS, Brewer HB, Jr., Davidson WS, et al. Cholesterol efflux and atheroprotection: advancing the concept of reverse cholesterol transport. Circulation. 2012;125:1905-1919.
61. Khera AV, Cuchel M, delaLlera-Moya M, et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med. 2011;364:127-135.
62. Rohatgi A, Khera A, Berry JD, et al. HDL cholesterol efflux capacity and incident cardiovascular events. N Engl J Med. 2014; 371:2383-2393.
63. Saleheen D, Scott R, Javad S, et al. Association of HDL cholesterol efflux capacity with incident coronary heart disease events: a prospective case-control study. Lancet Diabetes Endocrinol. 2015;3: 507-513.
64. Zhang Y, Zanotti I, Reilly MP, Glick JM, Rothblat GH, Rader DJ. Overexpression of apolipoprotein A-I promotes reverse transport of cholesterol from macrophages to feces in vivo. Circulation. 2003;108:661-663.
65. Calabresi L, Franceschini G. High density lipoprotein and coronary heart disease: insights from mutations leading to low high density lipoprotein. Curr Opin Lipidol. 1997;8:219-224.
66. Gualandri V, Franceschini G, Sirtori CR, et al. Almilano apopro-tein: identification of the complete kindred and evidence of a dominant genetic transmission. Am J Hum Genet. 1985;37:1083-1097.
67. Nissen SE, Tsunoda T, Tuzcu EM, et al. Effect of recombinant Apo A-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA. 2003; 290:2292-2300.
68. Gille A, Easton R, D'Andrea D, Wright SD, Shear CL. CSL112 enhances biomarkers of reverse cholesterol transport after single and multiple infusions in healthy subjects. Arterioscler Thromb Vasc Biol. 2014;34:2106-2114.
69. Chattopadhyay A, Navab M, Hough G, et al. A novel approach to oral apoA-I mimetic therapy. J Lipid Res. 2013;54:995-1010.
70. Navab M, Anantharamaiah GM, Hama S, et al. Oral administra-tionofanApo A-I mimetic Peptide synthesized from D-amino acids dramatically reduces atherosclerosisinmice independentofplasma cholesterol. Circulation. 2002;105:290-292.
71. Li X, Chyu KY, Faria Neto JR, Yano J, et al. Differential effects of apolipoprotein A-I-mimetic peptide on evolving and established atherosclerosis in apolipoprotein E-null mice. Circulation. 2004; 110:1701-1705.
72. Amar MJ, D'Souza W, Turner S, et al. 5A apolipoprotein mimetic peptide promotes cholesterol efflux and reduces atherosclerosis in mice. J Pharmacol Exp Ther. 2010;334:634-641.
73. Wool GD, Cabana VG, Lukens J, et al. 4F Peptide reduces nascent atherosclerosis and induces natural antibody production in apoli-poprotein E-null mice. FASEB J. 2011;25:290-300.
74. Getz GS, Reardon CA. The structure/function of apoprotein A-I mimetic peptides: an update. Curr Opin Endocrinol Diabetes Obes. 2014;21:129-133.
75. Picaud S, Wells C, Felletar I, et al. RVX-208, an inhibitor of BET transcriptional regulators with selectivity for the second bromodo-main. Proc Natl Acad Sci USA. 2013;110:19754-19759.
76. Nicholls SJ, Gordon A, Johannson J, et al. Apo A-I induction as a potential cardioprotective strategy: rationale for the SUSTAIN and ASSURE studies. Cardiovasc Drugs Ther. 2012;26:181-187.
77. Nicholls SJ, Puri R, Wolski K, et al. Effect of the BET protein inhibitor, RVX-208, on progression of coronary atherosclerosis: results of the phase 2b, randomized, double-blind, multicenter, ASSURE Trial. Am J Cardiovasc Drugs. In press.
78. Tzagournis M, Chiles R, Ryan JM, Skillman TG. Interrelationships of hyperinsulinism and hypertriglyceridemia in young patients with coronary heart disease. Circulation. 1968;38:1156-1163.
79. Levy RI, Glueck CJ. Hypertriglyceridemia, diabetes mellitus, and coronary vessel disease. Arch Intern Med. 1969;123:220-228.
80. Moberg B, Wallentin L. High density lipoprotein and other lipo-proteins in normolipidaemic and hypertriglyceridaemic (type IV) men with coronary artery disease. Eur J Clin Invest. 1981;11:433-440.
81. Sarwar N, Danesh J, Eiriksdottir G, et al. Triglycerides and the risk of coronary heart disease: 10, 158 incident cases among 262, 525 participants in 29 Western prospective studies. Circulation. 2007; 115:450-458.
82. Rapp JH, Harris HW, Hamilton RL, et al. Particle size distribution of lipoproteins from human atherosclerotic plaque: a preliminary report. J Vasc Surg. 1989;9:81-88.
83. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet. 2005;365:1415-1428.
84. Alberti KG, Eckel RH, Grundy SM, et al; International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; International Association for the Study of Obesity. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120:1640-1645.
85. Nordestgaard BG, Benn M, Schnohr P, Tybjaerg-Hansen A. Non-fasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA. 2007;298: 299-308.
86. Mora S, Rifai N, Buring JE, Ridker PM. Fasting compared with nonfasting lipids and apolipoproteins for predicting incident cardiovascular events. Circulation. 2008;118:993-1001.
87. Russo GT, Meigs JB, Cupples LA, et a;. Association of the Sst-I polymorphism at the APOC3 gene locus with variations in lipid levels, lipoprotein subclass profiles and coronary heart disease risk: the Framingham offspring study. Atherosclerosis. 2001;158:173-181.
88. Staels B, Dallongeville J, Auwerx J, Schoonjans K, Leitersdorf E, Fruchart JC. Mechanism of action of fibrates on lipid and lipo-protein metabolism. Circulation. 1998;98:2088-2093.
89. Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslip-idemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med. 1987;317:1237-1245.
90. Tepel M, Aspelin P, Lameire N. Contrast-induced nephropathy: a clinical and evidence-based approach. Circulation. 2006;113:1799-1806.
91. Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention ofcoronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med. 1999;341:410-418.
92. van Walraven C, Forster AJ, Parish DC, et al. Validation of a clinical decision aid to discontinue in-hospital cardiac arrest resuscitations. JAMA. 2001;285:1602-1606.
93. Bezafibrate Infarction Prevention Study. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. Circulation. 2000;102:21-27.
94. Keech A, Simes RJ, Barter P, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005;366:1849-1861.
95. ACCORD Study Group, Ginsberg HN, Elam MB, Lovato LC, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362:1563-1574.
96. Results of the low-dose (20 mg) pravastatin GISSI Prevenzione trial in 4271 patients with recent myocardial infarction: do stopped trials contribute to overall knowledge? GISSI Prevenzione Investigators (Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Mio-cardico). Ital Heart J. 2000;1:810-820.
97. Yokoyama M, Origasa H, Matsuzaki M, et al; Japan EPA lipid intervention study (JELIS) Investigators. Effects of eicosapenta-enoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet. 2007;369:1090-1098.
98. Saito Y, Yokoyama M, Origasa H, et al; Japan JELIS Investigators. Effects of EPA on coronary artery disease in hypercholesterolemic patients with multiple risk factors: sub-analysis of primary prevention cases from the Japan EPA Lipid Intervention Study (JELIS). Atherosclerosis. 2008;200:135-140.
99. Kwak SM, Myung SK, Lee YJ, Seo HG, Korean Meta-analysis Study G. Efficacy of omega-3 fatty acid supplements (eicosapen-taenoic acid and docosahexaenoic acid) in the secondary preven-tionofcardiovascular disease:ameta-analysisofrandomized, double-blind, placebo-controlled trials. Arch Intern Med. 2012;172: 686-694.
100. Stone NJ, Robinson JG, Lichtenstein AH, et al; American College of Cardiology/American Heart Association Task Forceon Practice Guideline Panel. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129:S1-S45.
101. Ballantyne CM, Braeckman RA, Soni PN. Icosapent ethyl for the treatment of hypertriglyceridemia. Expert Opin Pharmacother. 2013;14:1409-1416.
102. Jorgensen AB, Frikke-Schmidt R, Nordestgaard BG, Tybjaerg-Hansen A. Loss-of-function mutations in APOC3 and risk of isch-emic vascular disease. N Engl J Med. 2014;371:32-41.
103. TG and HDL Working Group of the Exome Sequencing Project, National Heart, Lung, Blood Institute, Crosby J, Peloso GM, Auer PL, et al. Loss-of-function mutations in APOC3, triglycerides, and coronary disease. N Engl J Med. 2014;371:22-31.
104. Brown WV, Baginsky ML. Inhibition of lipoprotein lipase by an apoprotein of human very low density lipoprotein. Biochem Bio-phys Res Commun. 1972;46:375-382.
105. Aalto-Setala K, Fisher EA, Chen X, et al. Mechanism of hypertri-glyceridemia in human apolipoprotein (apo) CIII transgenic mice. Diminished very low density lipoprotein fractional catabolic rate associated with increased apo CIII and reduced apo E on the particles. J Clin Invest. 1992;90:1889-1900.
106. Gaudet D, Brisson D, Tremblay K, et al. Targeting APOC3 in the familial chylomicronemia syndrome. N Engl J Med. 2014;371: 2200-2206.
107. Dijk W, Kersten S. Regulation of lipoprotein lipase by Angptl4. Trends Endocrinol Metab. 2014;25:146-155.
108. Lee EC, Desai U, Gololobov G, et al. Identification of a new functional domain in angiopoietin-like 3 (ANGPTL3) and angiopoi-etin-like 4 (ANGPTL4) involved in binding and inhibition of lipo-protein lipase (LPL). J Biol Chem. 2009;284:13735-13745.
109. Desai U, Lee EC, Chung K, et al. Lipid-lowering effects of anti-angiopoietin-like 4 antibody recapitulate the lipid phenotype found in angiopoietin-like 4 knockout mice. Proc Natl Acad Sci USA. 2007; 104:11766-11771.
110. Sahebkar A, Chew GT, Watts GF. Recent advances in pharmaco-therapy for hypertriglyceridemia. Prog Lipid Res. 2014;56:47-66.
111. Miller M, Stone NJ, Ballantyne C, et al; American Heart Association Clinical Lipidology, Thrombosis, and Prevention Committee of the Council on Nutrition, Physical Activity, and Metabolism; Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Cardiovascular Nursing; Council on the Kidney in Cardiovascular Disease. Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2011;123:2292-2333.
112. Sandholzer C, Hallman DM, Saha N, et al. Effects of the apolipo-protein(a) size polymorphism on the lipoprotein(a) concentration in 7 ethnic groups. Hum Genet. 1991;86:607-614.
113. Kukushkin SK, Shamarin VM, Manoshkina EM, Berzak NV, Petrosian K.[New drug formsofmolsidomine, Corvaton-forte and Corvaton-retard, and their antianginal efficacy in stenocardia patients]. Ter Arkh. 1996;68:29-30.
114. Koschinsky M, Boffa M. Lipoprotein(a) as a therapeutic target in cardiovascular disease. Expert Opin Ther Targets. 2014;18:747-757.
115. Nordestgaard BG, Chapman MJ, Ray K, et al; European Atherosclerosis Society Consensus Panel. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J. 2010;31:2844-2853.
116. Emerging Risk Factors Collaboration, Erqou S, Kaptoge S, Perry PL, et al. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA. 2009; 302:412-423.
117. Albers JJ, Slee A, O'Brien KD, et al. Relationship of apolipopro-teins A-1 andB, and lipoprotein(a)tocardiovascular outcomes: the AIM-HIGH trial (Atherothrombosis Intervention in Metabolic Syndromewith Low HDL/High Triglyceride andImpacton Global Health Outcomes). J Am Coll Cardiol. 2013;62:1575-1579.
118. Hoover-Plow J, Huang M. Lipoprotein(a) metabolism: potential sites for therapeutic targets. Metabolism. 2013;62:479-491.
119. Tsimikas S, Witztum JL. The role of oxidized phospholipids in mediating lipoprotein(a) atherogenicity. Curr Opin Lipidol. 2008; 19:369-377.
120. Kolski B, Tsimikas S. Emerging therapeutic agents to lower lipo-protein (a) levels. Curr Opin Lipidol. 2012;23:560-568.
121. Suk Danik J, Rifai N, Buring JE, Ridker PM. Lipoprotein(a), hormone replacement therapy, and risk of future cardiovascular events. J Am Coll Cardiol. 2008;52:124-131.
122. Tsimikas S, Viney NJ, Hughes SG, et al. Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study. Lancet. 2015;386:1472-1483.
123. Gaudet D, Methot J, Kastelein J. Gene therapy for lipoprotein lipase deficiency. Curr Opin Lipidol. 2012;23:310-320.
124. Grossman M, Rader DJ, Muller DW, et al. A pilot study of ex vivo gene therapy for homozygous familial hypercholesterolaemia. Nat Med. 1995;1:1148-1154.